ARTICLE | Top Story
NVS in-licenses Idenix's valopicitabine
March 30, 2006 2:14 AM UTC
Novartis (NVS; SWX:NOVN) exercised its option to license valopicitabine (NM283) from IDIX to treat HCV. The ribonucleoside analog is in separate Phase IIb trials for treatment-naive patients and treat...